![Thomas Andersson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Andersson
Corporate Officer/Principal chez
KDVENTURES AB
Profil
Thomas B. Andersson is currently a Director at Skogsmöllan AB, Kongsberg Beam Technology AS, and Investment Manager at Karolinska Development AB. He was previously the Chief Executive Officer at SpectraCure AB, Annexin Pharmaceuticals AB, and Lund University Bioscience AB from 2007 to 2012.
He was also the Chairman at ProNoxis AB and Director at DermaGen AB. Dr. Andersson holds a graduate and doctorate degree from the University of Lund.
Postes actifs de Thomas Andersson
| Sociétés | Poste | Début |
|---|---|---|
| KDVENTURES AB | Corporate Officer/Principal | - |
Kongsberg Beam Technology AS
 Kongsberg Beam Technology AS Packaged SoftwareTechnology Services Develops an AI-powered radiation therapy software | Directeur/Membre du Conseil | - |
Skogsmöllan AB
 Skogsmöllan AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical preparation services | Directeur/Membre du Conseil | - |
Anciens postes connus de Thomas Andersson
| Sociétés | Poste | Fin |
|---|---|---|
| ISOFOL MEDICAL AB | Directeur Général | 21/06/2023 |
Lund University Bioscience AB
 Lund University Bioscience AB Investment ManagersFinance LU Bio's investment objective is to create value growth in their innovations for all stakeholders such as the inventors, Lund University, investors and society. Their investment strategy seeks to invest in start-up, early-stage or early-expansion phase projects in the life science field which require capital. They invest across the Nordic region of Sweden, Denmark, Finland and Norway, with a particular focus on Sweden. LU Bio is an active investment partner. They provide both capital and industrial development know-how with the goal of accelerating efficient development of life science innovations. They look to develop high-growth, high-technology and focused portfolio firms. The firm aims to grow defensible and dominant market positions. | Directeur Général | 31/12/2012 |
| ANNEXIN PHARMACEUTICALS AB | Directeur Général | - |
| SPECTRACURE AB | Directeur Général | - |
ProNoxis AB
 ProNoxis AB Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs to treat chronic inflammation | Président | - |
Formation de Thomas Andersson
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
31
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
University of Lund
 University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
DermaGen AB
 DermaGen AB Pharmaceuticals: MajorHealth Technology Develops therapeutic peptides | Health Technology |
SpectraCure AB
 SpectraCure AB Electronic Equipment/InstrumentsElectronic Technology Develops and provides equipment for cancer treatment | Electronic Technology |
Lund University Bioscience AB
Lund University Bioscience AB Investment ManagersFinance LU Bio's investment objective is to create value growth in their innovations for all stakeholders such as the inventors, Lund University, investors and society. Their investment strategy seeks to invest in start-up, early-stage or early-expansion phase projects in the life science field which require capital. They invest across the Nordic region of Sweden, Denmark, Finland and Norway, with a particular focus on Sweden. LU Bio is an active investment partner. They provide both capital and industrial development know-how with the goal of accelerating efficient development of life science innovations. They look to develop high-growth, high-technology and focused portfolio firms. The firm aims to grow defensible and dominant market positions. | Finance |
ProNoxis AB
ProNoxis AB Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs to treat chronic inflammation | Health Technology |
Isofol Medical AB
 Isofol Medical AB Pharmaceuticals: MajorHealth Technology Provides novel folate-based pharmaceutical products | Health Technology |
Karolinska Development AB
 Karolinska Development AB Financial ConglomeratesFinance Operates as a life sciences investment company | Finance |
Annexin Pharmaceuticals AB
 Annexin Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops and manufactures drugs for cardiovascular diseases | Health Technology |
Skogsmöllan AB
Skogsmöllan AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical preparation services | Health Technology |
Kongsberg Beam Technology AS
Kongsberg Beam Technology AS Packaged SoftwareTechnology Services Develops an AI-powered radiation therapy software | Technology Services |
